Accolade, Inc. (NASDAQ:ACCD), a Delaware-based company offering business services with annual revenues of $447 million and a market capitalization of $576 million, announced on Monday that it has ...

SAN FRANCISCO & SEATTLE--(BUSINESS WIRE)--Today Transcarent announced the successful completion of its merger with Accolade, the leading health advocacy, expert medical opinion, and virtual ...

Accolade, Inc. SEATTLE, March 27, 2025 (GLOBE NEWSWIRE) -- Accolade (NASDAQ:ACCD) announced that Accolade stockholders voted to approve the merger with Transcarent at the Accolade special meeting ...

The devices are being recalled due to an increased risk for permanently entering Safety Mode. HealthDay News — Boston Scientific has issued a recall of Accolade pacemaker devices, according to a ...

Boston Scientific has issued a recall of Accolade pacemaker devices, according to a safety communication from the U.S. Food and Drug Administration. The Accolade devices under recall include the ...

Accolade Wines has announced that Robert Foye has decided to step down from his position as CEO, effective immediately. Foye's departure comes at a pivotal moment for the company, which is ...

S tephen H. Barnes, the Chief Financial Officer of Accolade, Inc. (NASDAQ:ACCD), recently sold shares of the company. According to a Form 4 filing with the Securities and Exchange Commission ...

Relive the golden era of retro sports gaming with the Accolade Sports Collection! From legendary baseball to electrifying street basketball, and epic winter and summer challenges, this collection ...

Transcarent has announced its acquisition of Accolade for $7.03 per share in cash, totaling approximately $621 million, creating a combined company with over 1,400 employer and payer clients ...

A notable marriage is occurring in the world of digital health: Transcarent has claimed Accolade for $621 million. But by no means is this a marriage of equals given how the latter is being taken ...

Transcarent acquires Accolade for $7.03 per share in cash, valuing the deal at $621 million, a 110% premium over its Jan. 7 stock price. The merger combines Transcarent's AI-powered care offerings ...

Transcarent will acquire Accolade for $7.03 per share in cash or $621 million in total. The transaction is expected to close during the 2025 second-quarter after gaining approval from Accolade ...